237 related articles for article (PubMed ID: 25460507)
21. Amyloid pathology arrangements in Alzheimer's disease brains modulate in vivo seeding capability.
Duran-Aniotz C; Moreno-Gonzalez I; Gamez N; Perez-Urrutia N; Vegas-Gomez L; Soto C; Morales R
Acta Neuropathol Commun; 2021 Mar; 9(1):56. PubMed ID: 33785065
[TBL] [Abstract][Full Text] [Related]
22. Aβ and Tau Prions Causing Alzheimer's Disease.
Condello C; Merz GE; Aoyagi A; DeGrado WF; Prusiner SB
Methods Mol Biol; 2023; 2561():293-337. PubMed ID: 36399277
[TBL] [Abstract][Full Text] [Related]
23. Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer's-like disease in mice.
von Linstow CU; Waider J; Grebing M; Metaxas A; Lesch KP; Finsen B
Alzheimers Res Ther; 2017 Sep; 9(1):74. PubMed ID: 28899417
[TBL] [Abstract][Full Text] [Related]
24. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.
Kung MP; Skovronsky DM; Hou C; Zhuang ZP; Gur TL; Zhang B; Trojanowski JQ; Lee VM; Kung HF
J Mol Neurosci; 2003 Feb; 20(1):15-24. PubMed ID: 12663930
[TBL] [Abstract][Full Text] [Related]
25. Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone.
Purro SA; Farrow MA; Linehan J; Nazari T; Thomas DX; Chen Z; Mengel D; Saito T; Saido T; Rudge P; Brandner S; Walsh DM; Collinge J
Nature; 2018 Dec; 564(7736):415-419. PubMed ID: 30546139
[TBL] [Abstract][Full Text] [Related]
26. E22G Pathogenic Mutation of β-Amyloid (Aβ) Enhances Misfolding of Aβ40 by Unexpected Prion-like Cross Talk between Aβ42 and Aβ40.
Yoo BK; Xiao Y; McElheny D; Ishii Y
J Am Chem Soc; 2018 Feb; 140(8):2781-2784. PubMed ID: 29425039
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous in vitro formation of supramolecular beta-amyloid structures, "betaamy balls", by beta-amyloid 1-40 peptide.
Westlind-Danielsson A; Arnerup G
Biochemistry; 2001 Dec; 40(49):14736-43. PubMed ID: 11732892
[TBL] [Abstract][Full Text] [Related]
28. Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.
Miners JS; Clarke P; Love S
Brain Pathol; 2017 May; 27(3):305-313. PubMed ID: 27248362
[TBL] [Abstract][Full Text] [Related]
29. Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients.
Watts JC; Condello C; Stöhr J; Oehler A; Lee J; DeArmond SJ; Lannfelt L; Ingelsson M; Giles K; Prusiner SB
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10323-8. PubMed ID: 24982139
[TBL] [Abstract][Full Text] [Related]
30. Experimental traumatic brain injury induces rapid aggregation and oligomerization of amyloid-beta in an Alzheimer's disease mouse model.
Washington PM; Morffy N; Parsadanian M; Zapple DN; Burns MP
J Neurotrauma; 2014 Jan; 31(1):125-34. PubMed ID: 24050316
[TBL] [Abstract][Full Text] [Related]
31. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.
Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG
J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661
[TBL] [Abstract][Full Text] [Related]
32. Prions, prionoids and pathogenic proteins in Alzheimer disease.
Ashe KH; Aguzzi A
Prion; 2013; 7(1):55-9. PubMed ID: 23208281
[TBL] [Abstract][Full Text] [Related]
33. Two structurally defined Aβ polymorphs promote different pathological changes in susceptible mice.
Gomez-Gutierrez R; Ghosh U; Yau WM; Gamez N; Do K; Kramm C; Shirani H; Vegas-Gomez L; Schulz J; Moreno-Gonzalez I; Gutierrez A; Nilsson KPR; Tycko R; Soto C; Morales R
EMBO Rep; 2023 Aug; 24(8):e57003. PubMed ID: 37424505
[TBL] [Abstract][Full Text] [Related]
34. Disruption of amyloid plaques integrity affects the soluble oligomers content from Alzheimer disease brains.
Jimenez S; Navarro V; Moyano J; Sanchez-Mico M; Torres M; Davila JC; Vizuete M; Gutierrez A; Vitorica J
PLoS One; 2014; 9(12):e114041. PubMed ID: 25485545
[TBL] [Abstract][Full Text] [Related]
35. Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.
Reinert J; Richard BC; Klafki HW; Friedrich B; Bayer TA; Wiltfang J; Kovacs GG; Ingelsson M; Lannfelt L; Paetau A; Bergquist J; Wirths O
Acta Neuropathol Commun; 2016 Mar; 4():24. PubMed ID: 26955942
[TBL] [Abstract][Full Text] [Related]
36. Aβ seeding potency peaks in the early stages of cerebral β-amyloidosis.
Ye L; Rasmussen J; Kaeser SA; Marzesco AM; Obermüller U; Mahler J; Schelle J; Odenthal J; Krüger C; Fritschi SK; Walker LC; Staufenbiel M; Baumann F; Jucker M
EMBO Rep; 2017 Sep; 18(9):1536-1544. PubMed ID: 28701326
[TBL] [Abstract][Full Text] [Related]
37. The Prion-Like Properties of Amyloid-β Assemblies: Implications for Alzheimer's Disease.
Walker LC; Schelle J; Jucker M
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27270558
[TBL] [Abstract][Full Text] [Related]
38. Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains.
Yuan J; Xiao X; McGeehan J; Dong Z; Cali I; Fujioka H; Kong Q; Kneale G; Gambetti P; Zou WQ
J Biol Chem; 2006 Nov; 281(46):34848-58. PubMed ID: 16987816
[TBL] [Abstract][Full Text] [Related]
39. The amyloid-β degradation intermediate Aβ34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease.
Kirabali T; Rigotti S; Siccoli A; Liebsch F; Shobo A; Hock C; Nitsch RM; Multhaup G; Kulic L
Acta Neuropathol Commun; 2019 Dec; 7(1):194. PubMed ID: 31796114
[TBL] [Abstract][Full Text] [Related]
40. Iron treatment inhibits Aβ42 deposition in vivo and reduces Aβ42/Aβ40 ratio.
Shen X; Liu J; Fujita Y; Liu S; Maeda T; Kikuchi K; Obara T; Takebe A; Sayama R; Takahashi T; Matsue A; Sera K; Michikawa M; Komano H; Zou K
Biochem Biophys Res Commun; 2019 May; 512(4):653-658. PubMed ID: 30791980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
